Ariflo (SB 207499), a second generation phosphodie...[Pulm Pharmacol Ther. 1999]

SearchDatabase nameforSearch term

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.

Division of Cardiovascular and Pulmonary Research, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, 19406, USA.

PMID: 10373396 [PubMed - indexed for MEDLINE]

ReviewABCD of the phosphodiesterase family: interaction and differential activity in COPD.
Halpin DM. Int J Chron Obstruct Pulmon Dis. 2008; 3(4):543-61.

[Int J Chron Obstruct Pulmon Dis. 2008]
ReviewPhosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.
Currie GP, Butler CA, Anderson WJ, Skinner C. Br J Clin Pharmacol. 2008 Jun; 65(6):803-10. Epub 2008 Mar 13.

[Br J Clin Pharmacol. 2008]
ReviewAn update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
Giembycz MA. Br J Clin Pharmacol. 2006 Aug; 62(2):138-52.

[Br J Clin Pharmacol. 2006]
» See all...

Your browsing activity is empty.

Activity recording is turned off.

Display Show